Geron Corporation
GERN•NASDAQ•Healthcare•Biotechnology

About Geron

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOHarout Semerjian
Founded1990
IPO DateJune 30, 1996
Employees229
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitewww.geron.com
Phone650 473 7700
Address
919 East Hillsdale Boulevard, Suite 250 Foster City, California 94404 United States

Corporate Identifiers

CIK0000886744
CUSIP374163103
ISINUS3741631036
EIN75-2287752
SIC2834

Leadership Team & Key Executives

Harout Semerjian
Chief Executive Officer, President and Director
Michelle J. Robertson
Executive Vice President, Chief Financial Officer, Treasurer and Principal Financial and Accounting Officer
Dr. Joseph Emile Eid M.D.
Executive Vice President of Research and Development and Chief Medical Officer
Shanthakumar Tyavanagimatt
Senior Vice President and Chief Technical Officer
Dawn Schottlandt CFA
Senior Vice President of Investor Relations and Corporate Affairs
Scott Samuels
Executive Vice President, Chief Legal Officer and Secretary
Aron Feingold
Vice President of Investor Relations and Corporate Communications
Shannon T. Odam
Executive Vice President and Chief People Officer
Bryan Ridgell
Senior Vice President of Portfolio and Project Management and Chief of Staff
Ahmed ElNawawi
Executive Vice President and Chief Commercial Officer